You are subscribed to one or more CDC code set email subscription services. Subscription links are available on each of the pages below.
Code Set Update Publication Date: April 06, 2021
Release Notes: This release includes the Vaccine Code Set Updates.
General Note regarding this release: Codes included with “Last Update” dates February 1 to April 6, 2021 to reflect the changes and additions in this release. It includes the following code set updates:
A. Vaccine Code Updates
1) COVID-19 Potential Pre-EUA Vaccine Code Additions and Updates:
COVID-19 Vaccine Codes and Crosswalks for one additional vaccine have been included in this release in anticipation of potential vaccine availability under Emergency Use Authorization (EUA). These codes will become effective if and only when the Food and Drug Administration (FDA) authorizes use of COVID-19 vaccine(s) under an EUA and ACIP votes to recommend the vaccines. The advance release of these codes is intended to help end user organizations prepare their systems ahead of vaccine distribution.
The CVX codes are listed as active. If EUA authorization and ACIP recommendation are not received, the codes will be inactivated. The NDC codes are currently listed by the FDA as “unauthorized” and these NDC codes will be activated upon receipt of an EUA authorization.
A separate downloadable table of just COVID-19 codes is also available on the CDC website vaccine code sets page and has been updated to reflect new NDCs for the COVID-19 vaccine and the new CPT codes.
https://www.cdc.gov/vaccines/programs/iis/code-sets.html
The AMA COVID-19 CPT codes for these potential EUA vaccines are also available and included in the CPT to CVX crosswalk downloadable file. American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are available on the AMA web site:
https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes
The codes and crosswalks for candidate COVID-19 vaccines will continue to be released in phases as the late-stage clinical trials for candidate vaccines progress.
One potential new EUA candidate vaccine is included in this release as follows:
Product Name: Novavax COVID-19 Vaccine: The CVX Code and Product are new in this release. Pending EUA
CPT and NDC codes are not yet available
- CVX Code = 211, “SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose”
- MVX Code = NVX, “Novavax, Inc.”
- Product/Tradename = “Novavax COVID-19 Vaccine”
Additional NDCs for the Moderna COVID-19 Vaccine. Authorized under EUA Amendment- The following NDCs are for a new larger fill multi-dose vial 7 mL, base number of extractable doses = 14. This vial has over-fill that allows 15 doses as a possible maximum that might be extractable
- NDCs for 5mL multi-dose vial remain active
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX
Code |
|---|
Moderna COVID-19 Vaccine | Moderna US, Inc. | 80777-0273-98 | 80777-0273-15 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose | MOD |
|---|
2) CVX Additions – Not Covid Related
- Vaccine Group = “Ebola”
- CVX Code = 204, “Ebola Zaire vaccine, live, recombinant, 1mL dose”
- Associated Product = “ERVEBO (Ebola Zaire Vaccine Live)”
This vaccine product is not yet FDA licensed and does not have approved NDCs
- CVX Code = 214, “Ebola, unspecified”
3) NDC Additions and Updates – Not COVID-19 Related:
The following NDCs were added
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX
Code |
|---|
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 49281-0182-25 | 49281-0182-00 | 200 | influenza, Southern Hemisphere, pediatric, preservative free | PMC |
|---|
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 49281-0321-50 | 49281-0321-88 | 201 | influenza, Southern Hemisphere, preservative free | PMC |
|---|
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 49281-0337-15 | 49281-0337-78 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
|---|
The following NDC pairs were retired – no new NDCs added at this time
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 | CVX Code | CVX Description | MVX
Code |
|---|
HAVRIX | GlaxoSmithKline Biologicals SA | 58160-0826-11 | 58160-0826-01 | 52 | Hep A, adult | SKB |
|---|
HAVRIX | GlaxoSmithKline Biologicals SA | 58160-0825-11 | 58160-0825-01 | 83 | Hep A, ped/adol, 2 dose | SKB |
|---|
FluMist Quadrivalent | MedImmune, LLC | 66019-0307-10 | 66019-0307-01 | 149 | influenza, live, intranasal, quadrivalent | MED |
|---|
